Abstract
While pancreatic cancer has an inherited or rapidly acquired chemoresistance, a meta-analysis of data from published clinical trials reported a significant improvement in overall survival (OS) among patients receiving chemotherapy [1]. Nowadays, gemcitabine is widely accepted as the standard first-line therapy and as the reference treatment arm for clinical trials in this patient population [2, 3]. However, its anti-tumoral activity is disappointing because the response rate is around 10%, median survival about 6 months, and 1-year OS around 20%.
Original language | English |
---|---|
Title of host publication | Imaging Tumor Response to Therapy |
Publisher | Springer-Verlag Italia s.r.l. |
Pages | 127-140 |
Number of pages | 14 |
ISBN (Print) | 9788847026131, 9788847026124 |
DOIs | |
Publication status | Published - Jan 1 2012 |
ASJC Scopus subject areas
- Medicine(all)
- Biochemistry, Genetics and Molecular Biology(all)